Oral Communications

About this session

Oral communications: OC29 Prognostic value of plasma p-tau217 for short- and long-term risk of cognitive impairment; OC30 LM11A-31 reduces CSF levels of eMTBR-tau243: a retrospective analysis of a phase 2a safety and exploratory biomarker trial in mild-moderate Alzheimer's disease; OC31 Relative Impact of Multidomain Lifestyle Interventions on Cardiovascular Risk Factor Change and Cognition over 24 months in the U.S. POINTER TRIAL; OC32 Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson's paradox; OC33 Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score; OC34 Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer's disease: data from PET, MRI and CSF with long-term follow-up; OC35 Longitudinal characterization of tau PET accumulation and spread anchored to amyloid and tau positivity timelines.

Speakers

• MD

  Marissa Denkinger

  Banner Sun Health Research Institute

  Chair

• FL

  Frank Longo

  Stanford University

  Chair